178 related articles for article (PubMed ID: 21729522)
21. Correlation between flow cytometric identification of CD33-positive cells and morphological evaluation of myeloblasts in bone marrow of patients with acute myeloblastic leukemia.
Oka S; Muroi K; Matsuyama T; Sato K; Ueda M; Toshima M; Suzuki T; Ozaki K; Mori M; Takubo T; Nagai T; Hanafusa T; Ozawa K
Hematology; 2009 Jun; 14(3):133-8. PubMed ID: 19490757
[TBL] [Abstract][Full Text] [Related]
22. Rapid identification of specific DNA aptamers precisely targeting CD33 positive leukemia cells through a paired cell-based approach.
Yang C; Wang Y; Ge MH; Fu YJ; Hao R; Islam K; Huang P; Chen F; Sun J; Hong F; Naranmandura H
Biomater Sci; 2019 Feb; 7(3):938-950. PubMed ID: 30519686
[TBL] [Abstract][Full Text] [Related]
23. Immunophenotype distinction between acute promyelocytic leukaemia and CD15- CD34- HLA-DR- acute myeloid leukaemia with nucleophosmin mutations.
Ferrari A; Bussaglia E; Úbeda J; Facchini L; Aventin A; Sierra J; Nomdedéu JF
Hematol Oncol; 2012 Sep; 30(3):109-14. PubMed ID: 21812014
[TBL] [Abstract][Full Text] [Related]
24. [CD13- and CD33-negative acute myelocytic leukemia (FAB classification; M2) with morphological changes and CD13 expression on recurrence].
Aoyama Y; Yamane T; Kanashima H; Takeoka Y; Koh K; Nakao Y; Yamamura R; Nakamae H; Ohta K; Inoue T; Hino M; Tatsumi N
Rinsho Ketsueki; 2001 Apr; 42(4):314-20. PubMed ID: 11400303
[TBL] [Abstract][Full Text] [Related]
25. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).
Baer MR; Stewart CC; Dodge RK; Leget G; Sulé N; Mrózek K; Schiffer CA; Powell BL; Kolitz JE; Moore JO; Stone RM; Davey FR; Carroll AJ; Larson RA; Bloomfield CD
Blood; 2001 Jun; 97(11):3574-80. PubMed ID: 11369653
[TBL] [Abstract][Full Text] [Related]
26. Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells.
Hauswirth AW; Florian S; Printz D; Sotlar K; Krauth MT; Fritsch G; Schernthaner GH; Wacheck V; Selzer E; Sperr WR; Valent P
Eur J Clin Invest; 2007 Jan; 37(1):73-82. PubMed ID: 17181570
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
[TBL] [Abstract][Full Text] [Related]
28. Immunological classification of acute myeloblastic leukemias: relevance to patient outcome.
Casasnovas RO; Slimane FK; Garand R; Faure GC; Campos L; Deneys V; Bernier M; Falkenrodt A; Lecalvez G; Maynadié M; Béné MC
Leukemia; 2003 Mar; 17(3):515-27. PubMed ID: 12646939
[TBL] [Abstract][Full Text] [Related]
29. Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia.
Bae J; Martinson JA; Klingemann HG
Cell Immunol; 2004 Jan; 227(1):38-50. PubMed ID: 15051513
[TBL] [Abstract][Full Text] [Related]
30. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
[TBL] [Abstract][Full Text] [Related]
31. CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.
Willier S; Rothämel P; Hastreiter M; Wilhelm J; Stenger D; Blaeschke F; Rohlfs M; Kaeuferle T; Schmid I; Albert MH; Binder V; Subklewe M; Klein C; Feuchtinger T
Blood; 2021 Feb; 137(8):1037-1049. PubMed ID: 33094319
[TBL] [Abstract][Full Text] [Related]
32. Expression of multidrug resistance P-glycoprotein in myeloid progenitor cells of different phenotype: comparison between normal bone marrow cells and leukaemia cells.
Takeshita A; Shinjo K; Ohnishi K; Ohno R
Br J Haematol; 1996 Apr; 93(1):18-21. PubMed ID: 8611458
[TBL] [Abstract][Full Text] [Related]
33. [A clinical and laboratory study on acute myeloid leukemia with t(6;9)(p23;q34)].
Wang Y; Xue Y; Chen S; Wu Y; Pan J; Zhang J; Shen J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):34-7. PubMed ID: 20140864
[TBL] [Abstract][Full Text] [Related]
34. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines.
Naito K; Takeshita A; Shigeno K; Nakamura S; Fujisawa S; Shinjo K; Yoshida H; Ohnishi K; Mori M; Terakawa S; Ohno R
Leukemia; 2000 Aug; 14(8):1436-43. PubMed ID: 10942240
[TBL] [Abstract][Full Text] [Related]
35. Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens.
Le Dieu R; Taussig D; Lister TA; Gribben JG
J Immunol Methods; 2009 Aug; 348(1-2):95-100. PubMed ID: 19576900
[TBL] [Abstract][Full Text] [Related]
36. CD133-2 (AC141) expression analysis in acute leukemia immunophenotyping in correlation to CD34 and P-glycoprotein.
Guenova M; Balatzenko G
Hematology; 2008 Jun; 13(3):137-41. PubMed ID: 18702870
[TBL] [Abstract][Full Text] [Related]
37. CD33 monoclonal antibody conjugated Au cluster nano-bioprobe for targeted flow-cytometric detection of acute myeloid leukaemia.
Retnakumari A; Jayasimhan J; Chandran P; Menon D; Nair S; Mony U; Koyakutty M
Nanotechnology; 2011 Jul; 22(28):285102. PubMed ID: 21654031
[TBL] [Abstract][Full Text] [Related]
38. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
Pagliaro LC; Liu B; Munker R; Andreeff M; Freireich EJ; Scheinberg DA; Rosenblum MG
Clin Cancer Res; 1998 Aug; 4(8):1971-6. PubMed ID: 9717827
[TBL] [Abstract][Full Text] [Related]
39. Acquisition of CD13 and CD33 expression at relapse on acute myeloid leukemia cells with an unusual phenotype: MPO+CD13-CD33-.
Kawada H; Ichikawa Y; Kobayashi N; Fukuda R; Yonekura S; Nagao T
Intern Med; 1993 Sep; 32(9):733-6. PubMed ID: 7908235
[TBL] [Abstract][Full Text] [Related]
40. Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow.
Ashman LK; Cambareri AC; To LB; Levinsky RJ; Juttner CA
Blood; 1991 Jul; 78(1):30-7. PubMed ID: 1712644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
